Specificity of U2 and GOL1 aptamers to EGFR-positive human glioblastoma cells in vitro
- Авторлар: Dzarieva F.1, Shamadykova D.1, Sluchanko O.2, Pavlova S.1, Fab L.1, Ryabova A.3, Panteleev D.1, Kopylov A.4, Usachev D.5, Golovin A.4,6, Pavlova G.1,5,6
-
Мекемелер:
- Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences (IHNA)
- Pirogov Russian National Research Medical University
- Prokhorov General Physics Institute
- M.V. Lomonosov Moscow State University (MSU)
- N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia
- I.M. Sechenov First Moscow State Medical University (MSMU)
- Шығарылым: Том 74, № 1 (2024)
- Беттер: 85-99
- Бөлім: ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ
- URL: https://journals.rcsi.science/0044-4677/article/view/259306
- DOI: https://doi.org/10.31857/S0044467724010097
- ID: 259306
Дәйексөз келтіру
Аннотация
Overexpression of the epidermal growth factor receptor (EGFR) or its mutations mediate signaling pathways leading to proliferation, invasion of tumor cells, as well as to an increase in their survival. Despite the success of the clinical use of antibodies against EGFR in patients with colorectal cancer and squamous cell carcinoma of the head and neck, their low effectiveness in glioblastoma has been shown. Therefore, for the treatment of gliomas, a specific EGFR drug is needed, capable of penetrating into the tumor focus in the brain, and having low immunogenicity.
In this work, aptamers – single-stranded DNA oligonucleotides specific to EGFR, U2 and Gol1 are presented as such a preparation. In this study, we obtained a cellular model of human glioma with EGFR and EGFRvIII overexpression, which showed the specificity of U2 and Gol1 aptamers to these receptors using classical methods, as well as the method of aptaimmunocytochemistry. A study of the effect of binding of the Gol1 aptamer to the EGFRvIII receptor on the next steps of the signaling pathway showed a change in the expression levels of genes associated with cell proliferation and survival (JUN, FOS, CCND1, PI3K and AKT3), while the U2 aptamer did not demonstrate a significant effect on cells in vitro.
These results showed that the Gol1 aptamer has therapeutic potential against human glioblastoma tumor cells overexpressing the EGFRvIII mutant type receptor.
Негізгі сөздер
Толық мәтін
Авторлар туралы
F. Dzarieva
Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences (IHNA)
Хат алмасуға жауапты Автор.
Email: dz.fatima@mail.ru
Ресей, Moscow
D. Shamadykova
Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences (IHNA)
Email: dz.fatima@mail.ru
Ресей, Moscow
O. Sluchanko
Pirogov Russian National Research Medical University
Email: dz.fatima@mail.ru
Ресей, Moscow
S. Pavlova
Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences (IHNA)
Email: dz.fatima@mail.ru
Ресей, Moscow
L. Fab
Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences (IHNA)
Email: dz.fatima@mail.ru
Ресей, Moscow
A. Ryabova
Prokhorov General Physics Institute
Email: dz.fatima@mail.ru
Ресей, Moscow
D. Panteleev
Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences (IHNA)
Email: dz.fatima@mail.ru
Ресей, Moscow
A. Kopylov
M.V. Lomonosov Moscow State University (MSU)
Email: dz.fatima@mail.ru
Ресей, Moscow
D. Usachev
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia
Email: dz.fatima@mail.ru
Ресей, Moscow
A. Golovin
M.V. Lomonosov Moscow State University (MSU); I.M. Sechenov First Moscow State Medical University (MSMU)
Email: dz.fatima@mail.ru
Ресей, Moscow; Moscow
G. Pavlova
Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences (IHNA); N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia; I.M. Sechenov First Moscow State Medical University (MSMU)
Email: lkorochkin@mail.ru
Ресей, Moscow; Moscow; Moscow
Әдебиет тізімі
- Каприн А. Д. Злокачественные новообразования в России в 2021 г. МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022.
- Babic I., Anderson E. S., Tanaka K., Guo D., Masui K., Li B., Zhu S., Gu Y., Villa G. R., Akhavan D., Nathanson D., Gini B., Mareninov S., Li R., Camacho C. E., Kurdistani S. K., Eskin A., Nelson S. F., Yong W. H., Cavenee W. K.,
- Cloughesy T. F., Christofk H. R., Black D. L., Mischel P. S. EGFR mutation-induced alternative splicing of max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 2013. 17 (6): 1000–1008. https://doi.org/10.1016/j.cmet.2013.04.013
- Brand T. M., Iida M., Luthar N., Starr M. M., Huppert E. J., Wheeler D. L. Nuclear EGFR as a molecular target in cancer. Radiother. Oncol. 2013. 108 (3): 370–377. https://doi.org/10.1016/j.radonc.2013.06.010
- Ciznadija D., Liu Y., Pyonteck S. M., Holland E. C., Koff A. Cyclin D1 and Cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res. 2011. 71 (19): 6174–6183. https://doi.org/10.1158/0008– 5472.CAN-11–1031.
- Cooper A. J., Sequist L. V., Lin J. J. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat. Rev. Clin. Oncol. 2022. 19 (8): 499– 514. https://doi.org/10.1038/s41571–022–00639–9
- Cvrljevic A. N., Akhavan D., Wu M., Martinello P., Furnari F. B., Johnston A. J., Guo D., Pike L., Cavenee W. K., Scott A. M., Mischel P. S., Hoogenraad N. J., Johns T. G. Activation of Src induces mitochondrial localisation of de 2–7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science. 2011. 124 (17): 2938–2950. https://doi.org/10.1242/jcs.083295
- David J.-P., Mehic D., Bakiri L., Schilling A. F., Mandic V., Priemel M., Idarraga M. H., Reschke M. O., Hoffmann O., Amling M., Wagner E. F. Essential role of RSK2 in c-Fos–dependent osteosarcoma development. J Clin. Invest. 2005. 115 (3): 664–672. https://doi.org/10.1172/ JCI22877
- Feng H., Hu B., Jarzynka M. J., Li Y., Keezer S., Johns T. G., Tang, C. K., Hamilton, R. L., Vuori, K., Nishikawa, R., Sarkaria, J. N., Fenton, T., Cheng, T., Furnari, F. B., Cavenee, W. K., Cheng, S.-Y. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc. Nat. Acad. Sci. 2012. 109 (8): 3018–3023. https://doi.org/10.1073/pnas.1121457109
- Fiano V., Ghimenti C., Schiffer D. Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans. Neurosci. Letters. 2003. 347 (2): 111–115. https://doi.org/10.1016/ S0304–3940(03)00615–3
- Goto N., Suzuki, H., Tanaka T., Ishikawa K., Ouchida T., Kaneko M. K., Kato Y. EMab-300 detects mouse epidermal growth factor receptor-expressing cancer cell lines in flow cytometry. Antibodies (Basel, Switzerland). 2023. 12 (3): 42. https://doi.org/10.3390/antib12030042
- Hammer S., Tschiatschek B., Flamm C., Hofacker I. L., Findeiß S. RNAblueprint: flexible multiple target nucleic acid sequence design. Bioinformatics. 2017. 33 (18): 2850–2858. https://doi.org/10.1093/bioinformatics/ btx263
- Hammer S., Wang W., Will S., Ponty Y. Fixed-parameter tractable sampling for RNA design with multiple target structures. BMC Bioinformatics. 2009. 20 (1): 209. https://doi.org/10.1186/s12859–019–2784–7
- Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022. 12 (1): 31–46. https://doi.org/ 10.1158/2159–8290.CD-21–1059
- Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell. 2011. 144 (5): 646–674. https://doi. org/10.1016/j.cell.2011.02.013
- Horvath S., Zhang B., Carlson M., Lu K. V., Zhu S., Felciano R. M., Laurance M. F., Zhao W., Qi S., Chen Z., Lee Y., Scheck A. C., Liau L. M., Wu H., Geschwind D. H., Febbo P. G., Kornblum H. I., Cloughesy T. F., Nelson S. F., Mischel P. S. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proceedings of the National Academy of Sciences. 2006. 103(46: 17402–17407. https://doi.org/10.1073/ pnas.0608396103
- Kappelmann M., Bosserhoff A., Kuphal S. AP-1/c-Jun transcription factors: Regulation and function in malignant melanoma. Eur. J. Cell Biol. 2014. 93 (1–2): 76–81. https://doi.org/10.1016/j.ejcb.2013.10.003
- Kopylov A. M., Fab L. V., Antipova O., Savchenko E. A., Revishchin A. V., Parshina V. V., Pavlova S. V., Kireev I. I., Golovin A. V., Usachev D. Y., Pavlova G. V. RNA aptamers for theranostics of glioblastoma of human brain. Biochemistry (Moscow). 2021. 86(8): 1012–1024. https://doi.org/10.1134/S0006297921080113
- Lao Y.-H., Phua K. K.L., Leong K. W. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano. 2015. 9 (3), 2235–2254. https://doi. org/10.1021/nn507494p
- Linder M., Glitzner E., Srivatsa S., Bakiri L., Matsuoka K., Shahrouzi P., Dumanic M., Novoszel P., Mohr T., Langer O., Wanek T., Mitterhauser M., Wagner E. F., Sibilia M. EGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling. EMBO Mol. Med. 2018. 10: e9408. (11). https://doi.org/10.15252/ emmm.201809408
- Mayer I. A., Arteaga C. L. The PI3K/AKT pathway as a target for cancer treatment. Ann. Rev. Med. 2016. 67 (1): 11–28. https://doi.org/10.1146/annurev-med-062913–051343
- Odajima T., Sasaki Y., Tanaka N., Kato-Mori Y., Asanuma H., Ikeda T., Satoh M., Hiratsuka H., Tokino T., Sawada N. Abnormal β-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features. Hum. Pathol. 2005. 36 (3): 234–241. https://doi.org/10.1016/j. humpath.2004.12.009
- Oprita A., Baloi S.-C., Staicu G.-A., Alexandru O., Tache D. E., Danoiu S., Micu E. S., Sevastre A.-S. Updated insights on EGFR signaling pathways in glioma. Int. J. Mol. Sci. 2021. 22 (2): 587. https://doi.org/10.3390/ijms22020587
- Pavlova G., Kolesnikova V., Samoylenkova N., Drozd S., Revishchin A., Usachev D., Kopylov A. Novel weapon to conquer human glioblastoma: G-quadruplexes and neuro-inducers. 2021.
- Pawson T. Specificity in signal transduction. Cell. 2004. 116 (2): 191–203. https://doi.org/10.1016/S0092–8674(03) 01077–8
- Peng L., Liang Y., Zhong X., Liang Z., Tian Y., Li S., Liang J., Wang R., Zhong Y., Shi Y., Zhang X. Aptamer-conjugated gold nanoparticles targeting epidermal growth factor receptor variant III for the treatment of glioblastoma. Int. J. Nanomed. 2020. 15: 1363– 1372. https://doi.org/10.2147/IJN.S238206
- Peurala E., Koivunen P., Haapasaari K.-M., Bloigu R., Jukkola-Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res.. 2013. 15 (1): R5. https://doi. org/10.1186/bcr3376
- Ratushny, V., Astsaturov, I., Burtness, B.A., Golemis, E.A., & Silverman, J. S. Targeting EGFR resistance networks in head and neck cancer. Cell. Signal. 2009. 21 (8): 1255–1268. https://doi.org/10.1016/j.cellsig.2009.02.021
- Reuter J. S., Mathews D. H. RNA structure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics. 2010. 11 (1): 129. https://doi.org/ 10.1186/1471–2105–11–129
- Shen Q., Uray I. P., Li Y., Krisko T. I., Strecker T. E., Kim H.-T., Brown P. H. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2008. 27 (3): 366–377. https://doi.org/ 10.1038/sj.onc.1210643
- Sugawa N., Ekstrand A. J., James C. D., Collins V. P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Nat. Acad. Sci. 1990. 87 (21): 8602–8606. https://doi.org/10.1073/pnas.87.21.8602
- Wan Y., Kim Y., Li N., Cho S. K., Bachoo R., Ellington A. D., Iqbal S. M. Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. Cancer Res. 2010. 70 (22): 9371–9380. https://doi.org/10.1158/ 0008–5472.CAN-10–0568
- Ward A. F., Braun B. S., Shannon K. M. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012. 120 (17): 3397–3406. https://doi.org/10.1182/ blood-2012–05–378596
- Wilson T., Karajannis M., Harter D. Glioblastoma multiforme: State of the art and future therapeutics. Surg. Neurol. Int. 2014. 5 (1): 64. https://doi.org/10.4103/ 2152–7806.132138
- Wu X., Liang H., Tan Y., Yuan C., Li S., Li X., Li G., Shi Y., Zhang X. Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. PLoS ONE. 2014. 9 (3): e90752. https://doi.org/10.1371/ journal.pone.0090752
- Xia W., Wei Y., Du Y., Liu J., Chang B., Yu Y.-L., Huo L.-F., Miller S., Hung M.-C. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol. Carcinogen. 2009. 48 (7): 610–617. https://doi.org/10.1002/mc.20504
- Yu J. S. L., Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016. 143 (17): 3050–3060. https://doi.org/10.1242/dev.137075
- Zhang X., Zhao M., Huang A., Fei Z., Zhang W., Wang X. The effect of cyclin D expression on cell proliferation in human gliomas. J. Clin. Neurosci. 2005. 12 (2), 166–168. https://doi.org/10.1016/j.jocn.2004.03.036
- Zhou J., Wu Z., Wong G., Pectasides E., Nagaraja A., Stachler M., Zhang H., Chen T., Zhang H., Liu J. Bin, Xu X., Sicinska E., Sanchez-Vega F., Rustgi A. K., Diehl J. A., Wong K.-K., Bass A. J. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat. Commun. 2017. 8 (1): 13897. https://doi.org/10.1038/ncomms13897
- Zhu G., Chen X. Aptamer-based targeted therapy. Adv. Drug Del. Rev. 2018. 134: 65–78. https://doi.org/ 10.1016/j.addr.2018.08.005
- Zok T., Antczak M., Zurkowski M., Popenda M., Blazewicz J., Adamiak R. W., Szachniuk M. RNApdbee 2.0: multifunctional tool for RNA structure annotation. Nucl. Acids Res. 2018. 46 (W1): W30–W35. https://doi.org/ 10.1093/nar/gky314